Cargando…
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Asthma is a complex, multifactorial disease that is underpinned by airway inflammation. A variety of cytotoxic substances are released into the airway from infiltrating inflammatory cells, especially the eosinophil. These cytotoxic substances, including reactive oxygen metabolites, produce damage to...
Autores principales: | Torphy, T J, Barnette, M S, Hay, D W, Underwood, D C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1566970/ https://www.ncbi.nlm.nih.gov/pubmed/7705312 |
Ejemplares similares
-
New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021) -
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
por: Mokra, Daniela, et al.
Publicado: (2021) -
Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury
por: Zhaleh, Mohsen, et al.
Publicado: (2014) -
Phosphodiesterase 4 inhibitors attenuate virus‐induced activation of eosinophils from asthmatics without affecting virus binding
por: Sabogal Piñeros, Yanaika Shari, et al.
Publicado: (2020) -
Rolipram: Eotaxin and phosphodiesterase IV inhibitor versus bronchial hyper-reactivity response
por: Khan, Hamza Hassan, et al.
Publicado: (2015)